When cardiology forgets to ask why Authors: Francesco Tona Published: 2025 ABSTRACT AbstractContemporary cardiology faces a paradox: unprecedented technological capability coincides with declining scientific curiosity and clinical judgement. This manuscript examines the shift from question-driven, physiologic medicine to an approach dominated by procedural feasibility, commercial influence and algorithmic decision-making. Advances such as transcatheter interventions, advanced imaging and artificial intelligence have broadened therapeutic options but also encouraged action to precede reasoning, allowing anatomical suitability to overshadow clinical appropriateness and patient-centred values.The paper describes how industry pressures, guideline structures and training environments normalise interventionist reflexes and weaken the discipline of restraint, while research increasingly prioritises surrogate outcomes and validation of existing technologies. In response, the manuscript advocates for restoring the ‘why’ in cardiology through renewed critical thinking, meaningful outcomes and ethically grounded decisions. This requires cultural, educational and structural reform so that technology enhances rather than displaces the scientific and humanistic foundations of the field.Keywords: Education, Medical; Ethics, Medical; Quality of Health Care ‘Quod fieri potest, non continuo faciendum est’ Not everything that can be done must be done (Ethical maxim-unattributed) Cardiology has never been more powerful. We can replace valves through catheters, visualise vessels in stunning detail, and predict events with algorithms trained on vast datasets. Yet amid this technological triumph, a quiet crisis has emerged: we have stopped asking why. Too often, the availability of highly effective technologies can create a subtle drift in practice patterns, leading us at times to act not because an intervention is clearly necessary, but because it is readily possible and increasingly routine. Transcatheter procedures, advanced imaging and artificial intelligence (AI) have accelerated our field into a constant state of motion. Along the way, science has yielded to capability. Hypotheses are out. Tools are in. Restraint is obsolete. We are no longer thinking. We are executing. From curiosity to capability Science begins with a question; technology begins with a solution. For decades, cardiology advanced through careful observation, physiologic reasoning and incremental innovation guided by scientific need. Today, that order is reversed. A new device appears, and adoption precedes reflection. Only later do we debate indications, endpoints and evidence. When transcatheter valves were first introduced, they were intended for patients deemed inoperable. Now they are routinely offered to nonagenarians with frailty, cognitive decline and advanced comorbidities—individuals whose survival is unlikely to change and whose quality of life is already fragile. Why do we proceed? Because the anatomy fits. The procedure is efficient. The complication rate is low. The marketing is persuasive. And because saying yes is easier than saying no. Yet this very ease—this natural momentum toward doing more—sits within a broader evolution of our tools. An evolution that is not inherently problematic; many innovations have expanded therapeutic possibilities and improved outcomes. But it also exposes a persistent tension: technological capability often advances faster than the reflective frameworks needed to guide its use. The undeniable achievements of modern cardiology It is important to acknowledge that the extraordinary technological evolution of cardiology has profoundly improved patient outcomes across multiple domains. Over the past two decades, transcatheter aortic valve implantation has transformed the prognosis of elderly and high-risk patients once considered inoperable, offering shorter recovery times, reduced suffering and meaningful gains in life expectancy and functional status.1 2 Percutaneous coronary intervention—supported by safer stents, physiologic lesion assessment and potent adjunctive pharmacology—has dramatically improved the management of acute coronary syndromes, reducing mortality and enabling rapid revascularisation with minimal invasiveness.3 Equally transformative has been the progress in advanced imaging. High-resolution CT, cardiac MRI and 3D echocardiography now allow clinicians to characterise anatomy, function and tissue composition with unprecedented precision, enabling earlier diagnosis, better risk stratification and individualised treatment planning.4 Meanwhile, AI–supported decision tools are beginning to assist clinicians in detecting arrhythmias, identifying subtle imaging abnormalities and predicting adverse events, providing an additional layer of support in complex cases.5 Modern cardiology has also benefited from widespread adoption of wearable and remote monitoring technologies, which allow early detection of atrial fibrillation, continuous rhythm surveillance, remote optimisation of heart failure therapy and more timely clinical intervention.6 These advances have not only contributed to longer survival but have also significantly enhanced quality of life, reduced hospitalisation rates and made cardiovascular care more accessible and less burdensome for many patients. These achievements are remarkable and must be fully recognised. They stand as proof that technology, when aligned with thoughtful clinical reasoning, can elevate the practice of cardiology and restore health with efficiency and compassion. When feasibility replaces judgement Despite these profound and undeniable benefits, the success of technology has also created new challenges. Even while technology has enhanced our ability to treat disease, medicine can drift from patient-centred to procedure-centred care when feasibility becomes the primary driver of decision-making. Anatomical feasibility has replaced clinical appropriateness as the main driver of decision-making.7 Once a patient is deemed ‘suitable’ for a technology, the intervention proceeds. Success is defined by deployment, not by outcome. In this environment, futility becomes proceduralised. We can now deliver a flawless therapy that provides no meaningful benefit to the patient—yet everyone leaves satisfied. The operator succeeded. The system functioned. The metrics improved. But that is not care. It is a process. The concern is not the existence of powerful tools, but the risk that their efficiency and elegance may overshadow the harder, slower work of individualised clinical judgement. Commercial influence: the silent driver Some components of this shift may be influenced not only by scientific progress but also by the commercial forces that inevitably accompany technological innovation. Industry plays an essential role in advancing cardiology, yet its influence extends far beyond funding. It shapes conferences, guidelines, research agendas, and even trainee expectations. Technologies are not merely adopted; they are promoted, incentivised and normalised. Procedures such as transcatheter valve replacement or left atrial appendage occlusion are no longer viewed solely as therapeutic options—they are also products. Their success depends not only on patient outcomes but on procedural volume. As a result, uptake itself becomes the goal. In this system, evidence rarely leads to practice; it often follows, serving to justify decisions already made. The death of restraint There was a time when clinical restraint was considered a virtue. Today, it can feel almost subversive. Contemporary training emphasises volume, complexity and technical mastery. Young cardiologists learn to optimise, deliver and perform—but rarely to pause. Few are taught to ask whether an intervention is truly necessary, or how to say no. Clinical judgement has been replaced by protocolised testing. Wearables generate endless data; AI highlights theoretical risks. CT, MRI and echocardiography are ordered reflexively rather than thoughtfully. This is not progress. It is automation mistaken for medicine. This is not a criticism of advanced training or procedural expertise—both are essential to modern cardiology—but a reminder that technical mastery must coexist with the disciplined practice of asking whether an intervention aligns with a patient’s values and expected benefit. AI: outsourcing thought AI represents the ultimate technological seduction. It promises efficiency, precision and objectivity—but it also risks eroding the foundations of clinical reasoning.8 AI excels at prediction, though it often does so without offering transparent explanations. Its logic is hidden, its inner workings opaque, yet clinicians are encouraged to trust it. As we increasingly rely on machine-generated outputs, the cognitive loop shortens. The patient becomes a data point. The physician becomes a validator. In this process, curiosity fades quietly in the background. What was meant to assist clinical thought begins to substitute for it. When used appropriately, AI has the potential to enhance—not replace—clinical judgement, offering new tools for risk prediction and early diagnosis. Yet without a critical framework, its strengths risk becoming vulnerabilities. Science or system? The transformation under way is not only clinical—it is epistemological. The very definition of science is shifting. Investigator-initiated research is in decline, replaced by industry-sponsored trials designed primarily to validate existing technologies.9 Surrogate endpoints dominate. Randomised studies ask narrow questions with limited clinical relevance, while negative results often remain unpublished. Increasingly, we are not exploring the unknown but confirming the expected. What was once an enterprise of discovery risks becoming one of maintenance—sustaining systems rather than advancing understanding. What are we losing? We are losing the ability to think critically. We are losing the habit of asking, what matters to this patient? We are losing the courage to doubt, to pause and to resist. Most concerning, we are losing the distinction between doing more and doing better. Precision without purpose is not progress. Volume without value is not success. Mastery of tools is not wisdom. Recognising the tremendous value that innovation has brought to patient care does not diminish the need for vigilance; rather, it underscores the responsibility to ensure that the momentum of technological progress remains anchored to meaningful clinical benefit. Reclaiming the why This perspective is not a rejection of innovation, nor a nostalgia for a pre-technical era, but a call for thoughtful integration of technology within the broader framework of clinical wisdom. Technology must serve medicine, not define it. We must re-teach the value of uncertainty, the discipline of restraint, and the centrality of the patient. Because when we stop asking why, we stop being physicians. We become technicians of possibility—skilled in execution but estranged from meaning. That is not the future cardiology deserves. How do we rebalance? Reclaiming medicine as a science—not merely a sequence of technological acts—requires more than introspection. It calls for a renewed commitment to the structures, habits and cultural foundations that have historically guided clinical judgement. The goal is not to restrain innovation but to ensure that its extraordinary potential remains anchored to meaningful patient benefit. To move towards this balance, several areas of practice deserve reconsideration. A first and fundamental step involves rethinking how we train the next generation of cardiologists. Contemporary training models reward procedural volume, technical mastery and adherence to algorithms, yet often leave little room to cultivate the more delicate art of clinical judgement. We need environments in which trainees are explicitly taught to navigate uncertainty, to weigh benefits against burdens, and to recognise when restraint is an ethical act rather than a missed opportunity. Case discussions focused on frailty, multimorbidity, cognitive decline and expectations of benefit can help deepen this skill, reinforcing the idea that reasoning is as essential as execution. A similar shift is needed in the way guidelines are written and applied. Too often, anatomical feasibility becomes the primary determinant of care, overshadowing considerations of appropriateness. Guidelines should instead reflect the full clinical landscape—integrating frailty assessments, functional trajectories, patient preferences and cognitive status alongside anatomical criteria. Even language matters: an intervention described as ‘appropriate’ should imply demonstrable patient-centred benefit, not merely technical success. When guidelines acknowledge complexity, they help protect clinicians from the silent drift towards default proceduralism. Research, too, must evolve. Much of contemporary clinical investigation is designed to validate existing technologies rather than to define their true boundaries. The field would benefit from studies that ask harder questions: when does an intervention cease to provide benefit? Which patients are least likely to gain? Which outcomes matter most to them? Trials that prioritise patient-centred endpoints—functional recovery, independence, symptom relief—are essential for restoring relevance. Equally important is support for investigator-initiated research and the publication of negative results, both of which act as safeguards against unchecked expansion of interventions whose utility may be marginal. None of this can occur without addressing the broader ecosystem in which cardiology operates. Industry has driven enormous progress, but its influence on education, research and clinical culture must be recognised with clarity. Greater transparency, boundaries between scientific exchange and commercial messaging, and independent processes for guideline development are essential. What we need is not suspicion but what might be called cultural immunity: the ability to recognise when enthusiasm for a technology reflects genuine clinical value and when it reflects the subtle weight of external incentives. Finally, even the daily workflow of clinical practice must evolve to support reflective decision-making. Structured discussions of expected benefit for high-risk or borderline candidates, multidisciplinary deliberation in cases of uncertain utility, and explicit documentation of the clinical rationale—including the outcomes that matter most to the patient—can transform judgement from an implicit process into an intentional and shared one. When these habits are woven into routine care, they make deliberation visible, reproducible and resilient to the pressures of speed and feasibility. Rebalancing cardiology in this way does not diminish the technological advances that have transformed patient care; rather, it ensures that those advances remain guided by purpose. Technology should expand our ability to heal, not our tendency to act without reflection. If we can restore this equilibrium—between capability and judgement, between success and meaning—then cardiology will continue to evolve not only as a powerful discipline, but as a profoundly human one. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. References